Focus: PentixaPharm is a specialized radiopharmaceutical company focused on diagnostic and therapeutic imaging agents for neurology and oncology indications, operating at mid-cap biotech scale with 51-200 employees.
Profile data last refreshed 11h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow PentixaPharm to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for PentixaPharm
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from PentixaPharm's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Pentixapharm Holding AG: FDA grants "Study May Proceed" for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review of the 2024 Consolidated Financial Statements - Eastern Progress
Pentixapharm Holding AG: FDA grants "Study May Proceed" for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review of the 2024 Consolidated Financial Statements Eastern Progress
Pentixapharm gets IND for Ga-68 pentixafor - AuntMinnie
Pentixapharm gets IND for Ga-68 pentixafor AuntMinnie
FDA Clears IND for Phase 3 Study of Cardiovascular Diagnostic Program - dicardiology.com
FDA Clears IND for Phase 3 Study of Cardiovascular Diagnostic Program dicardiology.com
Pentixapharm gets FDA clearance for phase 3 hypertension study By Investing.com - Investing.com South Africa
Pentixapharm gets FDA clearance for phase 3 hypertension study By Investing.com Investing.com South Africa
Pentixapharm Holding AG: FDA grants “Study May Proceed” for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review - TradingView
Pentixapharm Holding AG: FDA grants “Study May Proceed” for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review TradingView
Eckert & Ziegler, Thor Medical partner to supply lead-212 - AuntMinnie
Eckert & Ziegler, Thor Medical partner to supply lead-212 AuntMinnie
Showing 6 of 9 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo